JP7393385B2 - Inspection support equipment, methods and programs - Google Patents

Description

The technology of the present disclosure relates to an inspection support device, method, and program.

In recent years, wearable devices such as smart watches have been used to monitor biological information such as pulse, blood pressure, respiration, electrocardiogram, maximum oxygen intake, blood sugar equivalent value, and body temperature, and based on the monitored biological information, health promotion and disease prevention are being carried out. management is starting to become popular. In addition, by learning AI (Artificial Intelligence) using big data related to biological information, diseases and diseases that may be contracted with high accuracy are being identified.

Additionally, methods have been proposed for providing health management information to users using biometric information. For example, Patent Document 1 proposes a method of presenting a recommended action plan such as exercise content and meal content when an abnormality is found in the blood sugar level monitoring results obtained by a wearable terminal. In addition, in Patent Document 2, it is determined whether the postprandial blood sugar level obtained by a wearable terminal is within a set range, and if it is not within the set range, a recommended date and time for self-collection using a blood test kit. A method for notifying users has been proposed.

Japanese Patent Application Publication No. 2006-259827 International Publication No. 2019/188909

However, in the method described in Patent Document 1, only the recommended action plan is presented to the user. Therefore, with the method described in Patent Document 1, it is not possible to grasp the current state of biological information with high precision when an abnormal tendency is observed in the monitoring results. Further, the method described in Patent Document 2 only presents a recommended date and time for self-collection of blood using a blood test kit. Therefore, in the method described in Patent Document 2, even if an abnormal tendency is observed in the biological information as a result of monitoring, the user has no option of additional testing using a blood test kit. There is only blood sampling available.

The present disclosure has been made in view of the above circumstances, and aims to enable a user to take actions including tests according to abnormal trends in biological information.

An examination support device according to the present disclosure includes at least one processor, and the processor monitors the first biological information of a user to determine whether or not the first biological information tends to be abnormal; If the biometric information of the user has an abnormal tendency, a plurality of action candidates should be recommended to the user, including at least one test candidate for acquiring second biometric information related to the first biometric information. Determine action candidates, present a plurality of action candidates to the user , accept the specification of at least one item that will serve as an index when the user selects the presented action candidates, and change the display format according to the specified item. and presents action candidates .

"Present" means to make the action candidate recognizable to the user, such as displaying the action candidate on a display, outputting it from a device for display on a display, or outputting the action candidate by voice. Including.

In the test support device according to the present disclosure, the test candidates may include test candidates that can acquire second biological information with higher accuracy than the first biological information.

In the test support device according to the present disclosure, the item serves as an index when the user selects a test candidate included in the presented action candidates, and the processor presents the test candidate in a display format according to the specified item. It may be something.

In the inspection support device according to the present disclosure, the processor presents the user with a question for determining the display position of the inspection candidate on at least one scale according to at least one specified item, and The test candidates may be presented to the user in a display format in which the display position of the candidate is determined according to the answer to the question, and an icon representing the test candidate is displayed at the determined display position on the scale.

In the test support device according to the present disclosure, after displaying an icon representing a test candidate, the processor can accept a user's designation for adding an item, and when the item designation is added, the processor can add a test candidate to the test candidate. The display form of the represented icon may be updated.

In the test support device according to the present disclosure, the processor repeats accepting the specification of adding an item, presenting a question according to the added item, and updating the display mode of the test candidate until the test candidate is selected by the user. It may be something.

In the test support device according to the present disclosure, the items include the cost required for the test, the sense of security when collecting the specimen, the degree of restraint during the test, whether it is invasive or non-invasive, the time required until the test result is obtained, and various other items. It may include at least one of whether or not a disease risk check is included and the accuracy of the test.

In the test support device according to the present disclosure, the processor selectively determines test candidates from among a plurality of test methods that include designation of the type of the test subject and for acquiring second biological information from the test subject. It may be something that does.

In the test support device according to the present disclosure, the processor may determine test candidates according to the degree of abnormality tendency.

In the test support device according to the present disclosure, the processor may determine test candidates according to the elapsed time from the time when it is determined that the first biological information has an abnormal tendency to the current time.

In the test support device according to the present disclosure, the processor may determine test candidates according to risk factors possessed by the user.

In the test support device according to the present disclosure, the processor may present statistical information of test candidates selected in the past to the user.

In the test support device according to the present disclosure, the first biological information may be a blood sugar equivalent value having a correlation with the blood sugar level, and the second biological information may include at least one of the blood sugar level and HbA1c.

In the test support device according to the present disclosure, the abnormal tendency may be a postprandial hyperglycemia spike.

In the test support device according to the present disclosure, the processor may determine test candidates based on the user's meal content.

In the test support device according to the present disclosure, the first biological information is at least one of heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial oxygen saturation, and body temperature, and the second biological information is information on the user's disease. It may be a diagnosis result.

In the test support device according to the present disclosure, the processor may provide notification according to the result of monitoring the first biological information when it is determined that the first biological information does not have an abnormal tendency.

In the test support device according to the present disclosure, the first biological information may be acquired by a measuring device worn by the user.

In the test support device according to the present disclosure, the measuring device may be wearable.

In the test support device according to the present disclosure, if the processor cannot determine whether or not the first biological information tends to be abnormal, the processor may issue a notification to increase the wearing time of the measuring device.

The test support device according to the present disclosure may include a sensor that acquires first biological information.

The test support device according to the present disclosure may be wearable.

In the test support device according to the present disclosure, the action candidates may further include recommended actions for the user.

In the test support device according to the present disclosure, the processor acquires second biological information and determines whether to continue monitoring the first biological information according to the acquired second biological information. It's okay.

The test support method according to the present disclosure determines whether or not the first biological information tends to be abnormal by monitoring the first biological information of the user, and when the first biological information tends to be abnormal, determining a plurality of action candidates to be recommended to the user and including at least one test candidate for acquiring second biometric information related to the first biometric information; is presented to the user , a designation of at least one item serving as an index for the user to select the presented action candidates is accepted, and the action candidates are presented in a display format according to the designated item .

The test support program according to the present disclosure includes a procedure for determining whether or not the first biological information tends to be abnormal by monitoring the first biological information of the user; a step of determining a plurality of action candidates to be recommended to the user, including at least one test candidate for acquiring second biometric information related to the first biometric information; A procedure for presenting multiple action candidates to the user , a procedure for accepting the specification of at least one item that will be used as an index when the user selects the presented action candidates, and an action in a display format according to the specified item. This method causes a computer to execute the steps of presenting candidates .

According to the present disclosure, a user can take actions including an examination according to abnormal trends in biological information.

A schematic diagram showing the configuration of an inspection support system to which an inspection support device according to an embodiment of the present disclosure is applied. Hardware configuration diagram of the inspection support device according to this embodiment Hardware configuration diagram of wristwatch-type measuring device Hardware configuration diagram of a measuring device that measures glucose in interstitial fluid Functional configuration diagram of the inspection support device according to this embodiment Diagram showing diurnal blood sugar fluctuations in type 2 diabetic patients Table showing testing methods for biological information related to blood sugar equivalent values Flowchart showing processing performed in this embodiment Flowchart showing processing performed in this embodiment Diagram showing the notification screen when the blood sugar equivalent value does not have an abnormal trend Diagram showing the action candidate presentation screen Diagram showing an action candidate presentation screen displaying an explanation of the selected test candidate Diagram showing an action candidate presentation screen displaying statistical information of test candidates selected in the past Diagram showing an action candidate presentation screen displaying recommended action details Diagram showing a list screen of items that serve as indicators when the user selects test candidates Diagram showing the question presentation screen A diagram showing a presentation screen that presents test candidates to a user in a display format that displays test candidate icons on a scale. Diagram showing a list screen of items that serve as indicators when the user selects test candidates Diagram showing the question presentation screen A diagram showing a presentation screen that presents test candidates to the user in a display format that displays test candidate icons on a scale when two items are selected. Diagram showing a guide screen that guides you to a website that sells blood sugar level meters Diagram showing a guide screen that guides the user to hospitals where glucose tolerance tests can be performed Diagram showing the guidance screen for the next test Diagram showing a screen that asks the user about the results of a urine sugar test Diagram showing a notification screen to prompt the user to increase the amount of time the meter is worn Diagram showing the results of comparison between blood sugar equivalent monitoring results and test results conducted by the user through blood sampling Schematic diagram showing changes in heart rate fluctuations, etc. of patients infected with the new coronavirus infection Table showing testing methods related to new coronavirus infection A diagram showing a presentation screen that presents test candidates to the user in a display format that displays test candidate icons on a scale when two items are selected. A diagram showing a presentation screen that presents test candidates to the user in a display format that displays test candidate icons on a scale when two items are selected. Diagram showing the question presentation screen

[First embodiment]
Hereinafter, a first embodiment of the present disclosure will be described with reference to the drawings. FIG. 1 is a schematic diagram showing the configuration of an examination support system to which an examination support apparatus according to a first embodiment of the present disclosure is applied. As shown in FIG. 1, an inspection support system 1 according to the present embodiment includes a mobile terminal 2 such as a smartphone, and measuring instruments 3 and 4. The mobile terminal 2 and the measuring instruments 3 and 4 are capable of communicating with each other via short-range wireless communication such as Bluetooth (registered trademark). The mobile terminal 2 is communicably connected to the test server 6 via a wired or wireless network 5. The mobile terminal 2 is an example of an inspection support device according to this embodiment.

The measuring device 3 is a wristwatch-type wearable terminal such as a smart watch, and has a function of constantly measuring a blood sugar equivalent value that correlates with the user's blood sugar level. The blood sugar equivalent value is biological information that has a correlation with the blood sugar level and is measured by a method that does not involve blood sampling. Constantly measuring means that the blood sugar equivalent value is automatically measured at predetermined time intervals, such as 15 minutes, 30 minutes, etc., without the user instructing measurement. Note that the measuring device 3 may measure the blood sugar equivalent value at all times and also measure the blood sugar equivalent value when instructed by the user. Furthermore, the measuring device 3 may be of a type that is worn by the user only during measurement, such as a finger clip.

Further, the measuring device 3 is a non-invasive measuring device for blood sugar equivalent value, and derives the blood sugar equivalent value by analyzing a signal emitted by blood glucose by, for example, irradiating the user with infrared rays. Alternatively, the user's electrocardiogram is measured and a blood sugar equivalent value correlated with changes in the electrocardiogram is derived. The measuring device 3 transmits the derived blood sugar equivalent value to the mobile terminal 2.

The measuring device 4 is an invasive blood glucose equivalent value measuring device. For example, the measuring device 4 is worn by the user, constantly measures the glucose concentration in the interstitial fluid under the user's epidermis, and transmits the measured glucose concentration to the mobile terminal 2. For this purpose, the measuring device 4 has a needle-like filament 4A that is inserted under the user's epidermis. Since glucose concentration has a correlation with blood sugar level, it becomes a blood sugar equivalent value.

The blood sugar equivalent value measured by the measuring devices 3 and 4 is an example of first biological information. Note that the user only needs to have either one of the measuring instruments 3 and 4.

The mobile terminal 2 monitors the blood sugar equivalent values measured by the measuring devices 3 and 4 to determine whether the blood sugar equivalent values tend to be abnormal. When the blood sugar equivalent value tends to be abnormal, the mobile terminal 2 presents a plurality of action candidates to be recommended to the user. The action candidates include at least one test candidate for acquiring biological information related to blood sugar equivalent values measured by the measuring devices 3 and 4.

Here, in the present embodiment, the mobile terminal 2 determines whether the blood sugar equivalent value has an abnormal tendency by determining whether the blood sugar equivalent value is in a postprandial hyperglycemic spike state. Postprandial hyperglycemic spike is a symptom seen in the early stages of diabetes, and is a symptom in which the blood sugar level significantly increases about 1 to 2 hours after a meal, even if the fasting blood sugar level is within the normal range. If left untreated, postprandial hyperglycemic spikes can damage blood vessels, making arteriosclerosis and diabetic complications more likely. It is also believed that complications such as myocardial infarction, angina pectoris, and stroke are more likely to progress. This embodiment monitors the blood sugar equivalent value, and when it is determined that the blood sugar equivalent value has an abnormal tendency, it presents the user with a plurality of action candidates including recommended test candidates. The system allows users to take a test that can obtain biological information to accurately understand hyperglycemic spikes.

The network 5 is a wide area network (WAN) that connects the mobile terminal 2 and the test server 6 over a wide area via a public line network or a private line network.

The test server 6 is installed at a test center that supports tests related to blood sugar levels. The inspection server 6 has a function of providing the inspection support program according to this embodiment to the mobile terminal 2, and providing the portable terminal 2 with information necessary when the mobile terminal 2 executes the inspection support program. The inspection server 6 is a general-purpose computer installed with a software program that provides server functions.

The test center provides various support to users regarding tests related to blood sugar levels. For example, by providing an inspection support program according to this embodiment, support for a user to select an inspection method is provided. Furthermore, when the user selects a test method, the service supports the purchase of equipment and test kits necessary for the selected test, and supports the reservation of a test at a hospital. Tests are also performed using samples delivered by users and collected by the users themselves.

Next, the inspection support device according to this embodiment will be explained. First, with reference to FIG. 2, the hardware configuration of the inspection support apparatus according to this embodiment will be described. As shown in FIG. 2, a mobile terminal 2, which is an inspection support device according to the present embodiment, is a portable computer such as a smartphone, and has a CPU (Central Processing Unit) 11, a non-volatile storage 13, and a temporary storage area. A memory 16 is provided. The mobile terminal 2 also includes a touch panel 14 , a communication I/F (InterFace) 15 that performs short-range wireless communication, and a network I/F 17 that is wirelessly connected to the network 5 . The mobile terminal 2 also includes a camera 18 . The CPU 11 , storage 13 , touch panel 14 , communication I/F 15 , memory 16 , network I/F 17 , and camera 18 are connected to the bus 19 . Note that the CPU 11 is an example of a processor in the present disclosure.

The storage 13 is realized by an SSD (Solid State Drive), a flash memory, and the like. The inspection support program 12 installed in the mobile terminal 2 is stored in the storage 13 as a storage medium. The CPU 11 reads the inspection support program 12 from the storage 13, expands it into the memory 16, and executes the expanded inspection support program 12.

The touch panel 14 is made up of a liquid crystal display, an organic EL display, and the like, and displays various types of information related to processing performed by the mobile terminal 2. Furthermore, the touch panel 14 also has a function as an input device for performing various inputs to the mobile terminal 2.

The camera 18 photographs the user's meal, for example, in response to a user's instruction, thereby acquiring an image of the meal. The acquired meal image is stored in the storage 13. Alternatively, the information is transmitted to the test server 6 together with the blood sugar equivalent value monitoring results as described later, either according to the user's instructions or without waiting for the instructions.

The test support program 12 is stored in the test server 6 in a state that can be accessed from the outside, and is downloaded and installed on the mobile terminal 2 in response to a request.

Next, the measuring device will be explained. FIG. 3 explains the hardware configuration of the measuring instrument 3. The measuring instrument 3 is a wristwatch-type computer, and as shown in FIG. 3, includes a CPU 21, a nonvolatile storage 23, and a memory 26 as a temporary storage area. The measuring instrument 3 also includes a touch panel 24, a communication I/F 25 that performs short-range wireless communication, a network I/F 27 that is wirelessly connected to an external network (not shown), and a sensor 28. The CPU 21 , storage 23 , touch panel 24 , communication I/F 25 , memory 26 , network I/F 27 , and sensor 28 are connected to the bus 29 .

The storage 23 is realized by SSD, flash memory, and the like. The storage 23 serving as a storage medium stores a measurement program 22 installed in the measuring device 3 for measuring a blood sugar equivalent value. The CPU 21 reads the measurement program 22 from the storage 23, loads it into the memory 26, and executes the loaded measurement program 22.

The touch panel 24 is composed of a liquid crystal display, an organic EL, etc., and provides various displays related to the processing performed by the measuring instrument 3. Furthermore, the touch panel 24 also has a function as an input device for performing various inputs to the measuring instrument 3.

The sensor 28 includes, for example, an infrared light source and an infrared detector, and irradiates the user wearing the measuring device 3 with infrared rays, thereby detecting a signal emitted by glucose in the blood. The signal detected by the sensor 28 is analyzed by the CPU 21 that executes the measurement program 22, and a blood sugar equivalent value is derived. Moreover, the sensor 28 may measure an electrocardiogram. In this case, the measurement program 22 analyzes the electrocardiogram and derives a blood sugar equivalent value.

Note that the measurement program 22 is stored in the test server 6 in a state that can be accessed from the outside, and is downloaded and installed in the measuring instrument 3 according to a request. Alternatively, the measurement program 22 is downloaded to the mobile terminal 2, and then downloaded and installed in the measuring instrument 3 via near field communication with the mobile terminal 2.

In the measuring device 3, a sensor 28 detects a signal emitted by blood glucose at predetermined time intervals. The CPU 21 analyzes the signal using the measurement program 22 and derives a blood sugar equivalent value. Further, the CPU 21 transmits the derived blood sugar equivalent value to the mobile terminal 2 from the communication I/F 25.

Next, the measuring device 4 will be explained. FIG. 4 is a hardware configuration diagram of the measuring instrument 4. As shown in FIG. 4, the measuring device 4 is, for example, a measuring device described in Japanese Patent Publication No. 2016-520379, which is attached to the human body and measures the glucose concentration in the interstitial fluid under the epidermis as a blood sugar equivalent value. be. The measuring device 4 includes a processor 31, a memory 32 as a temporary storage area, a communication I/F 33 that performs short-range wireless communication, and a sensor 34. A needle-like filament 4A inserted under the epidermis is connected to the sensor 34. The processor 31, memory 32, communication I/F 33, and sensor 34 are composed of an integrated circuit (ASIC (Application Specific Integrated Circuit)) 35 for measuring glucose in interstitial fluid.

In the measuring device 4, the sensor 34 detects a signal representing the glucose concentration in the subepidermal interstitial fluid at predetermined time intervals or in response to measurement instructions from the user. Processor 31 analyzes the signal and derives the glucose concentration. Further, the processor 31 transmits the derived glucose concentration to the mobile terminal 2 from the communication I/F 33.

Next, the functional configuration of the inspection support device according to this embodiment will be explained. FIG. 5 is a diagram showing the functional configuration of the inspection support device, that is, the mobile terminal 2 according to this embodiment. As shown in FIG. 5, the mobile terminal 2 includes an information acquisition section 41, a determination section 42, a determination section 43, and a presentation section 44. The CPU 11 functions as an information acquisition section 41 , a determination section 42 , a determination section 43 , and a presentation section 44 by executing the inspection support program 12 . In the following description, it is assumed that the user has the measuring device 3 and monitors the blood sugar equivalent value measured by the measuring device 3 using the mobile terminal 2.

The information acquisition unit 41 acquires the blood sugar equivalent value transmitted from the communication I/F 25 of the measuring device 3 by receiving it through the communication I/F 15. Note that since the measuring device 3 basically transmits the blood sugar equivalent value all the time, that is, at predetermined time intervals, the information acquisition unit 41 always acquires the blood sugar equivalent value. The blood sugar equivalent value acquired by the information acquisition unit 41 is stored in the storage 13 in association with the date and time of acquisition.

The determination unit 42 determines whether or not the blood sugar equivalent value has an abnormal tendency by monitoring the blood sugar equivalent value acquired by the information acquisition unit 41. Specifically, the determination unit 42 determines whether the blood sugar equivalent value is in a state of postprandial hyperglycemia spike. Here, postprandial hyperglycemia will be explained. FIG. 6 is a diagram showing diurnal blood sugar fluctuations in type 2 diabetic patients. In FIG. 6, the horizontal axis is the time of the day (24 hours), and the vertical axis is the blood sugar level (mg/dL). The solid line indicates the blood sugar level of patients with HbA1c (hemoglobin A1c) of 9% or higher. The dashed line shows the blood glucose level of patients with HbA1c less than 7-8%. The dashed-dotted line indicates the blood glucose level of patients with HbA1c of 6.5% to less than 7%. Further, FIG. 6 shows the fluctuation in blood sugar level when a person had breakfast at around 8 o'clock, lunch at around 12 o'clock, and dinner at around 19 o'clock. Note that HbA1c is glucose bound to hemoglobin, which is a component of red blood cells in blood. HbA1c represents fluctuations in blood sugar over a 1-2 month period.

As shown in Figure 6, an increase in blood sugar level is seen after a meal regardless of the value of HbA1c, but the higher the HbA1c, the more pronounced the postprandial hyperglycemia spike, which causes a large rise in blood sugar level after breakfast. . In order to make it easier to understand the postprandial hyperglycemia spike after breakfast, a line is added at the 8 o'clock position in FIG.

The determining unit 42 monitors the blood sugar equivalent value transmitted from the measuring device 3, and determines that the blood sugar equivalent value is in an abnormal trend when the time fluctuation of the blood sugar equivalent value exceeds a predetermined threshold Th1. judge. In this embodiment, the time variation is the difference between the currently measured blood sugar equivalent value and the most recent blood sugar equivalent value. Further, the temporal fluctuation of the blood sugar equivalent value may be determined by taking into account blood sugar equivalent values acquired at a plurality of recent timings.

In the present embodiment, the determination unit 42 determines that the postprandial hyperglycemia spike is large when the fluctuation in the blood sugar equivalent value is equal to or greater than the threshold value Th2. Note that Th2>Th1. Further, the determination unit 42 determines that the postprandial hyperglycemia spike is small when the fluctuation in the blood sugar equivalent value is greater than or equal to the threshold Th3 and less than the threshold Th2. Note that Th2>Th3>Th1. Furthermore, when the fluctuation in the blood sugar equivalent value is greater than or equal to the threshold Th1 and less than the threshold Th3, the determination unit 42 determines that the blood sugar level is high and that caution is required. Further, the determining unit 42 determines that the fasting blood sugar level is high when the fasting blood sugar level is equal to or higher than the predetermined threshold Th4.

Note that when the determination unit 42 determines that the blood sugar equivalent value does not have an abnormal tendency, it issues a notification to that effect. The notification will be explained later.

On the other hand, the user may transmit the meal time from the measuring device 3 to the mobile terminal 2 in order to assist the determination in the determination unit 42 . Alternatively, the meal time may be input into the mobile terminal 2. Alternatively, the meal may be photographed using the camera 18 of the mobile terminal 2, and the photographed time may be used to assist in determination. Thereby, it is possible to determine the rising tendency of the blood sugar equivalent value based on the accurate meal time.

The determining unit 43 determines a plurality of action candidates to be recommended to the user when the determining unit 42 determines that the blood sugar equivalent value tends to be abnormal. The action candidates include at least one test candidate for acquiring biological information related to blood sugar equivalent values. Further, the determining unit 43 determines test candidates according to the degree of abnormality tendency.

FIG. 7 is a table showing testing methods for biological information related to blood sugar equivalent values. In FIG. 7, the test type, test location, cost, required time, and measured biological information are shown as test information for 12 types of test methods (1) to (12).

The blood sugar equivalent monitoring of test method (1) is a test in which the blood sugar equivalent value is monitored using the measuring device 4. The self-urinary sugar test of test method (2) is a test that detects urinary sugar contained in the user's urine using a dedicated measuring device. Urinary sugar is glucose that leaks into the urine. Additionally, some urine sugar tests use test strips. Testing methods (3) to (6) are self-drawn blood tests that can be completed at home (testing methods (3) and (4)), and self-drawn blood is sent to a testing center, which is an external testing facility. (inspection methods (5) and (6)). Note that test method (3) is a test that measures blood sugar level using a blood sugar level meter (SMBG: Self Monitoring of Blood Glucose). (Several items) described in test method (4) means that the test method performs several tests in addition to blood sugar level. In FIG. 7, some inspection methods are indicated by "+α".

Note that testing methods (1) and (2) have lower accuracy than testing by blood sampling. However, by referring to the test results by test methods (1) and (2) in addition to the blood sugar equivalent value measured by the measuring device 3, the user's blood sugar trends can be better understood than when using only the blood sugar equivalent value measured by the measuring device 3. This allows for more accurate recognition.

Testing methods (7) to (9) at pharmacies, etc. are blood tests using test equipment installed at pharmacies, in front of stations, and at dedicated locations (for example, convenience stores). Testing methods (10) to (12) that are performed at a hospital are tests in which the user goes to the hospital and a medical worker takes a blood sample. Further, among the tests performed at the hospital, the GA test of test method (11) is a test for glycoalbumin, and the 1,5AG test is a test for 1,5-anhydro-D-glucitol. Glucoalbumin is a combination of albumin, a type of protein in serum, and glucose, and is biological information that allows us to know the status of blood sugar levels one to two weeks ago. 1,5AG is the second most abundant sugar in the blood after glucose. By measuring 1,5AG as biological information, it is possible to know the status of blood sugar levels over the past few days. The GA test, 1,5AG test, and glucose tolerance test are all tests specific to postprandial hyperglycemia. For this reason, "specialized testing" is indicated in the testing method column. Furthermore, in the test methods (6) and (9), 12 items and 13 items are described in the biological information column, respectively, which means that there are 12 and 13 test items, respectively. Note that these test items include tests that measure blood sugar levels and HbA1c as biological information.

Glucose, urine sugar, blood sugar level, HbA1c, glycoalbumin, and 1,5AG, which are biological information obtained by test methods (1) to (12), are examples of second biological information related to blood sugar equivalent value. .

Further, FIG. 7 shows various items that serve as indicators when the user selects the presented test candidates. Specifically, the cost required for the test (cost), the sense of security (feeling of security) when collecting the specimen, the degree of restraint during the test (restraint degree), whether it is invasive or non-invasive (invasiveness), and the test results. The following items are shown: the time required to obtain the results (required time), whether or not risk checks for various diseases are included (risk check), and the accuracy of the test (accuracy). The column for each item shows the degree of desirability for each testing method. The degrees of preference are designated by the symbols A, B, C, D and F in order of preference. A represents very preferable, B represents preferable, C represents not favorable, D represents unfavorable, and F represents extremely unfavorable.

Regarding cost, the lower the cost, the higher the degree of desirability. Regarding the sense of security, the lower the user's anxiety about sample collection (for example, blood collection), the greater the sense of security becomes. For example, a user feels a high sense of security when blood is drawn by a medical professional. Regarding the degree of restraint, the degree of desirability varies depending on whether the person goes out or not and the waiting time, and increases as the person does not go out and the waiting time is short. Note that the GA test, the 1,5AG test, and the glucose tolerance test are given a preferability level of "F" for the degree of restraint because there are a limited number of hospitals that can perform the tests.

Regarding invasiveness, the degree of preference increases when the specimen can be obtained without pain. In the glucose tolerance test, since it is necessary to collect blood three times after glucose loading, the preferability level for invasiveness is "F".

Regarding the required time, the shorter the time, the higher the degree of desirability. Regarding risk checks for various diseases, the degree of desirability increases when there are many test items and tests for diseases other than diabetes are included. Regarding accuracy, the higher the accuracy of detecting postprandial hyperglycemia, the higher the degree of desirability.

Further, FIG. 7 shows various abnormal trends in blood sugar equivalent values. Specifically, it has been shown that the postprandial hyperglycemic spike is large, the postprandial hyperglycemic spike is small, the fasting blood sugar is high, and that the blood sugar level requires attention (blood sugar level caution required). There is.

Further, in FIG. 7, for each abnormal tendency, a circle is given in the column of the test method to be used as a test candidate. In other words, when the postprandial hyperglycemia spike is large, five types of testing methods (3), (4), (6), including testing methods specialized for postprandial hyperglycemia (11), (12), are available at hospitals. (11) and (12) are marked with a circle. Note that for test methods (3), (4), and (6), postprandial blood sampling is essential for determining postprandial hyperglycemic spikes. If the postprandial hyperglycemia spike is small, ○ is given to eight testing methods (3) to (10), including testing methods (7) to (9) performed at home or at a pharmacy. Furthermore, if the fasting blood sugar level is high, multi-item test methods (4), (6), and (9) are marked with a circle. Further, when caution is required regarding the blood sugar level, the determination unit 43 marks the test methods (1) and (2) with a circle.

In this embodiment, the table shown in FIG. 7 is stored in the storage 13 as a table. The determining unit 43 refers to the table stored in the storage 13 and determines test candidates according to the abnormal tendency of the blood sugar equivalent value determined by the determining unit 42. Specifically, when the abnormal tendency determined by the determination unit 42 is a large postprandial hyperglycemia spike, the determination unit 43 refers to the table and selects test methods (3), (4), (6), ( 11) and (12) are determined as test candidates. Further, when the abnormal tendency determined by the determination unit 42 is a small postprandial hyperglycemia spike, the determination unit 43 determines test methods (3) to (10) as test candidates. Further, when the abnormal tendency determined by the determination unit 42 is that the fasting blood sugar level is high, the determination unit 43 determines test methods (4), (6), and (9) as test candidates. Further, when the abnormal tendency determined by the determination unit 42 is that the blood sugar level is high, the determination unit 43 determines test methods (1) and (2) as test candidates.

Note that when the user photographs a meal using the camera 18 of the mobile terminal 2, the determination unit 43 determines the meal content based on the image of the meal and determines test candidates according to the meal content. good. For example, if the abnormal tendency determined by the determination unit 42 is a small postprandial hyperglycemia spike, and the meal content is determined to be low in sugar, the postprandial hyperglycemia spike is small due to the influence of the meal. it is conceivable that. Therefore, the abnormal tendency of the blood sugar equivalent value was changed to a large postprandial hyperglycemia spike, and test methods (3), (4), (6), (11), and (12) were determined as test candidates. Good too.

The presentation unit 44 presents a plurality of action candidates including the test candidates determined by the determination unit 43 to the user. In this embodiment, the presentation unit 44 displays the test candidates determined by the determining unit 43 on the touch panel 14, thereby presenting the user with a plurality of action candidates including the test candidates.

The processing performed in this embodiment will be described below. 8 and 9 are flowcharts showing the processing performed in this embodiment. In order to monitor the blood sugar equivalent value, the information acquisition unit 41 monitors whether the communication I/F 15 has received the blood sugar equivalent value transmitted from the measuring device 3 (step ST1), and if step ST1 is affirmative, Then, the determining unit 42 first determines whether or not the blood sugar equivalent value tends to be abnormal (step ST2). If step ST2 is negative, the determining unit 42 notifies that the blood sugar equivalent value does not have an abnormal tendency (step ST3), and returns to step ST1. FIG. 10 is a diagram showing a notification screen when the blood sugar equivalent value does not have an abnormal tendency. As shown in FIG. 10, a notification 51 is displayed on the notification screen 50, which reads, "Your blood sugar level is not trending abnormally. Please continue with your current lifestyle."

If step ST2 is affirmed, the determination unit 42 determines the degree of abnormal tendency of the blood sugar equivalent value. First, the determination unit 42 determines whether the user's fasting blood sugar level is equal to or higher than the threshold value Th4 based on the monitoring result of the blood sugar equivalent value (step ST4). If step ST4 is affirmed, the determination unit 43 determines a test method for a case where fasting blood sugar is high as a test candidate (step ST5). When step ST4 is negative and following step ST5, the determining unit 42 determines whether the fluctuation in the blood sugar equivalent value is equal to or greater than the threshold value Th2 (step ST6).

If step ST6 is affirmed, the determining unit 43 determines, as a test candidate, a test method in which the postprandial hyperglycemia spike is large among the test methods included in the table shown in FIG. 7 (step ST7). If step ST6 is negative, the determining unit 42 determines whether the fluctuation value of the blood sugar equivalent value is greater than or equal to the threshold value Th3 and less than the threshold value Th2 (step ST8). When step ST8 is affirmed, the determining unit 43 determines, as a test candidate, a test method in which the postprandial hyperglycemia spike is small among the test methods included in the table shown in FIG. 7 (step ST9). If step ST8 is negative, the determining unit 43 determines, as a test candidate, a test method that requires careful attention to the blood sugar level among the test methods included in the table shown in FIG. 7 (step ST10). Following steps ST7, ST9, and ST10, the presenting unit 44 presents a plurality of action candidates including the determined test candidates to the user (step ST11).

FIG. 11 is a diagram showing an action candidate presentation screen. As shown in FIG. 11, a plurality of action candidates 53 are displayed on the action candidate presentation screen 52, including test candidates for a large postprandial hyperglycemia spike, for example. The action candidates 53 include five test candidates and one recommended action. Recommended actions represent actions recommended to the user. The five test candidates are test method (3): self-collection of blood glucose level at home, test method (4): self-collection of blood at home (several items), test method (6): self-collection of blood at home (multiple items), and test method (6): self-collection of blood at home (multiple items). (11) specialized tests at a hospital (GA test and 1,5AG test), and test method (12) a specialized test at a hospital (glucose tolerance test). The presentation screen 52 also includes a statistical information reference button 54, an item selection button 55, and a determination button 56. The statistical information reference button 54 is for displaying statistical information as described later. The item selection button 55 is used to display a list screen of items that serve as indicators when the user selects test candidates, as will be described later. The determination button 56 is for determining test candidates.

In addition, there are test candidates when fasting blood sugar levels are high, test candidates when postprandial hyperglycemic spikes are large, test candidates when postprandial hyperglycemic spikes are small, and test candidates when caution is required regarding blood sugar levels. may overlap. Therefore, for example, if the postprandial hyperglycemic spike is large and the fasting blood sugar level is high, the action candidates 53 will include both test candidates.

Each test candidate and recommended action included in the action candidates 53 can be selected, and when the user selects a test candidate or recommended action included in the action candidates, a description of the selected test candidate or recommended action is displayed. . For example, when the user selects "hospital, specialized test (glucose tolerance test)" from among the five test candidates, as shown in FIG. , go to Hospital A, Hospital B, or Hospital C and collect blood before drinking glucose, then 30, 60, and 120 minutes after drinking, and test the blood sugar level at each time. ” is displayed between the item selection button 55 and the enter button 56. When the user selects the OK button 56 in this state, the selected test candidate is determined as the test method to be performed by the user. The processing after the inspection method is determined will be described later.

Note that test methods (3), (4), and (6) require blood sampling after meals. Therefore, the explanation when test methods (3), (4), and (6) are selected includes that blood sampling after meals is essential.

Further, when the user selects the statistical information reference button 54, statistical information of test candidates selected in the past is displayed. Here, a plurality of test candidates are selected and presented to the user according to the abnormal tendency of the user's blood sugar equivalent value, and the user selects one test candidate from the plurality of test candidates and performs the test. The statistical information represents the rate at which each of a plurality of test candidates was selected in the past by the user currently conducting the test and/or other users. Note that the statistical information is derived by summing up which test candidates have been selected in the past with respect to test candidates with an abnormal tendency similar to the abnormal tendency of the user's blood sugar equivalent value. For example, if the abnormal tendency of the user's blood sugar equivalent value is a large postprandial hyperglycemia spike, statistical information about test methods (3), (4), (6), (11), and (12) is displayed. Further, if the abnormal tendency of the user's blood sugar equivalent value is a small postprandial hyperglycemia spike, statistical information regarding test methods (3) to (10) is displayed.

FIG. 13 is a diagram showing an action candidate presentation screen on which statistical information of test candidates is displayed. As shown in FIG. 13, statistical information 58 for each of the five test candidates presented is displayed between the item selection button 55 and the enter button 56. As shown in FIG. 13, in the statistical information 58, the rate at which each test candidate was selected in the past is shown as a percentage. The statistical information 58 is stored in the test server 6, and when the statistical information reference button 54 is selected, the mobile terminal 2 accesses the test server 6, acquires the statistical information 58, and presents it to the user.

Even when the statistical information 58 is displayed, if the user selects any test candidate and selects the determination button 56, the selected test candidate is determined as the test method to be performed by the user.

Further, when the user selects a recommended action included in the action candidates 53, the action recommended to the user is displayed according to the user's blood sugar equivalent value. For example, as shown in Figure 14, recommended action 59 is ``Be careful about what you eat.Eat vegetables first.Exercising after meals is effective in suppressing increases in blood sugar levels.'' is displayed between the item selection button 55 and the enter button 56.

After presenting the action candidates, the determining unit 43 determines whether the determination button 56 is selected (step ST12), and if step ST12 is affirmed, the process proceeds to step ST20, which will be described later. If step ST12 is negative, the determining unit 43 determines whether or not the item selection button 55 is selected (item selection; step ST13). If step ST13 is negative, the process returns to step ST11. If step ST13 is affirmed, the presentation unit 44 displays a list of items (step ST14).

FIG. 15 is a diagram showing a list screen displaying a list of items. As shown in FIG. 15, the item list screen 60 displays the text "Which item do you prioritize?". In addition, the list screen 60 includes items that serve as indicators when selecting test candidates, such as the cost required for the test, the sense of security when drawing blood, the degree of restraint during the test, whether it is invasive, and the time until test results are obtained. The time required for the test, the inclusion of risk checks for various diseases, and the accuracy of the test are displayed. Additionally, a check box 61 is provided to each item. The user specifies the item by checking the checkbox of any item that he/she wants to focus on when selecting examination information, and selects the item specification button 62. For this purpose, the determining unit 43 determines whether the item designation button 62 has been selected (step ST15). If step ST15 is negative, the process returns to step ST14. If step ST15 is affirmed, the determining unit 43 presents the user with a question for determining the display position of the test candidate on the scale described later, according to the specified item (step ST16).

FIG. 16 is a diagram showing a question presentation screen. For the sake of explanation, it is assumed here that the user has selected "time required until test results are obtained" as an item to be used as an index when selecting a test candidate. As shown in FIG. 16, four questions Q1 to Q4 are displayed on the question presentation screen 65. Question Q1 is ``Do you have a blood sugar level measuring device?'', Question Q2 is ``Do you have a self-blood sampling device (several items)?'', and Question Q3 is ``Do you have a blood glucose meter?'', and Question Q3 is ``Do you have a blood glucose meter?'' Do you have a kit?'' and question Q4 is ``When can you go to the hospital?''. The user answers YES or NO to questions Q1 to Q3, and if YES, inputs the date and time of blood collection in input boxes 67A to 67C. In addition, for question Q4, the date and time when you are likely to go to the hospital is input into the input box 67D. Here, it is assumed that the user answers NO to all of the questions Q1 to Q3 because he does not have a blood glucose level measuring device, a self-collecting blood measuring device, or a test kit for delivery. It is also assumed that tomorrow's date has been input for question Q4.

When the user selects the end answer button 66 after answering, the determining unit 43 determines the position at which the test candidate is displayed on the scale according to the specified item. The presentation unit 44 then presents the test candidates to the user in a display format that displays an icon representing the test candidate at the determined display position on the scale (presentation of test candidate scale; step ST17). Here, in this embodiment, "time required until test results are obtained" is selected as an index item when selecting test candidates. For this reason, the determining unit 43 derives the time required until the test result is obtained according to the answer to the question, and determines the display position of the test candidate on the scale representing the required time. The presentation unit 44 then presents the test candidates to the user in a display format that displays the test candidate icon at the determined display position on the scale.

FIG. 17 is a diagram showing a presentation screen that presents test candidates to the user in a display format in which test candidate icons are displayed on a scale. As shown in FIG. 17, a scale 69 representing the required time is displayed on the presentation screen 68, and icons 70A to 70E of five test candidates are displayed arranged along the scale 69 according to the required time. As shown in FIG. 17, the display positions on the scale 69 of icons 70A and 70B of test candidates corresponding to hospital test methods (11) and (12) are "tomorrow". This is because the user answered question Q4 that he could go to the hospital tomorrow. Further, the display position on the scale 69 of the test candidate icon 70C corresponding to the home self-blood sampling test method (4) and the test candidate icon 70D corresponding to the test method (3) is "3 days later". . "3 days" is the time required to deliver the blood glucose level measuring device, self-blood sampling measuring device, and shipping test kit from the testing center to the user. Furthermore, the display position on the scale 69 of the icon 70E of the test candidate corresponding to the test method (6), which is home self-blood sampling and delivery, is "7 days later." This is the time required for the test kit to be delivered from the test center to the user, the blood sample taken by the user to be delivered to the test center, the test to be performed at the test center, and the test results to be sent to the user's mobile terminal 2. be.

Note that if the user has a blood glucose level measuring device and answers that he or she will immediately collect blood, the required time will be, for example, "5 minutes." Furthermore, if the user has a test kit for delivery, three days, which is the number of days required to deliver the test kit to the user, is subtracted from seven days, and the required date and time is derived as "four days later."

The presentation screen 68 allows the user to recognize the required date and time for the presented test candidate at a glance. Thereby, it is possible to easily compare test candidates according to the items that the user considers important.

The user can select the test candidate icon on the presentation screen 68 and select the determination button 71 to determine the test method desired by the user. Furthermore, by selecting the item selection button 72, it is possible to additionally specify an item that will serve as an index when selecting a test candidate. For this purpose, following step ST17, the determining unit 43 determines whether the item selection button 72 has been selected (step ST18). If step ST18 is affirmed, the process returns to step ST14, and the processes from step ST14 to step ST18 are repeated. If step ST18 is negative, the determination unit 43 determines whether the determination button 71 has been selected (step ST19). If step ST19 is affirmed, the process proceeds to step ST20, which will be described later. If step ST19 is negative, the process returns to step ST17.

FIG. 18 is a diagram showing an item list screen displayed for the second time when step ST18 is affirmed. As shown in FIG. 18, among the checkboxes 61 displayed on the item list screen 60, the checkbox for "time required to obtain test results" has already been checked. The user can further select items on the item list screen 60. Here, it is assumed that the user further selects "cost required for examination." The determining unit 43 presents the user with a question for determining the display position of the test candidate on the scale according to the "cost required for the test".

FIG. 19 is a diagram showing a question presentation screen regarding "cost required for examination." As shown in FIG. 19, two questions Q5 and Q6 are presented on the question presentation screen 74. Question Q5 is ``Would you consider the initial investment for purchasing the measuring instrument?'' and Question Q6 is ``Would you consider transportation costs?''. The user answers the question with YES or NO. Here, it is assumed that the answer is YES to both questions Q5 and Q6. After answering, when the user selects the end answer button 75, the presentation unit 44 updates the display form of the icon representing the test candidate. That is, the determining unit 43 determines the display position of the test candidate on the additional scale according to the additionally designated item, and the presenting unit 44 displays the test candidate at the determined display position on the already presented scale and the additional scale. , the test candidates are presented to the user in a display format that displays an icon representing the test candidate.

Specifically, the determining unit 43 derives the cost required for the test according to the answer to the question, and determines the display position of the test candidate on the scale representing the cost required for the test. Then, the presentation unit 44 displays the test candidates to the user by displaying the scale of the required time and the scale of the cost required for the test so as to be orthogonal to each other, and displaying the test candidate icons at positions on the two orthogonal scales. present.

FIG. 20 is a diagram showing a presentation screen that presents test candidates to the user in a display format in which test candidate icons are displayed on a scale when two items are selected. As shown in FIG. 20, on the presentation screen 76, a scale 77 representing the cost is displayed orthogonal to a scale 69 representing the required time, and icons 70A to 70E of five test candidates are displayed according to the required time and cost. displayed in a dimensional arrangement. As shown in FIG. 20, the display position of the test candidate icons 70A and 70B corresponding to the hospital test methods (11) and (12) on the scale 69 is "tomorrow", and the display position on the scale 77 is The location is 3000 yen. Further, the display position on the scale 69 of the icon 70C of the test candidate corresponding to the test method (4) of self-collection of blood at home is "3 days later", and the display position on the scale 77 is 20,000 yen. The display position on the scale 69 of the icon 70D of the test candidate corresponding to the home self-blood sampling test method (3) is "3 days later", and the display position on the scale 77 is 7000 yen. Further, the display position on the scale 69 of the icon 70E of the test candidate corresponding to the test method (6), which is home self-collection and delivery of blood, is "7 days later", and the display position on the scale 77 is 5000 yen.

The presentation screen 76 allows the user to recognize the required date and time and cost of the presented test candidate at a glance. Thereby, it is possible to easily compare test candidates in consideration of both the required date and time and cost.

On the presentation screen 76, the user can select the test candidate icon and select the determination button 71 to determine the test method desired by the user. Furthermore, by further selecting the item selection button 72, it is possible to additionally specify an item that will serve as an index when selecting a test candidate. This makes it possible to add more items and compare test candidates until the user is satisfied.

When steps ST12 and ST19 are affirmed, the presentation unit 44 displays guidance regarding the testing method selected by the user on the touch panel 14 (step ST20). For example, if the user wants to check his or her blood sugar level periodically in the future and selects the testing method of self-collected blood glucose level measurement at home, the presentation unit 44 may display a blood glucose level using a self-monitoring of blood glucose level (SMBG). ) to guide users to websites that sell products. FIG. 21 is a diagram showing a guide screen of a website that sells blood glucose level measuring devices. As shown in FIG. 21, the guide screen 80 displays a plurality of websites where blood glucose level measuring devices can be purchased. By accessing the displayed website, the user can purchase a blood glucose level meter.

On the other hand, if the user wishes to firmly grasp the current status of his/her own blood sugar level and selects a glucose tolerance test at a hospital, the presentation unit 44 displays a glucose tolerance test at a glucose tolerance test near the user's home or workplace. Guide the user to hospitals where the test can be performed. FIG. 22 is a diagram showing a guide screen that guides the user to hospitals where a glucose tolerance test can be performed. As shown in FIG. 22, the guide screen 81 displays hospitals near the user's workplace that can perform a glucose tolerance test. Further, the presented hospital name can be selected, and when a hospital name is selected, a list 82 of dates and times at which a glucose tolerance test can be reserved is displayed. FIG. 22 shows a state in which hospital A has been selected and a list of available dates and times for hospital A is displayed. The user can make a reservation for a glucose tolerance test at the selected hospital by selecting the date and time marked with "○" and selecting the reservation button 83.

Following step ST20, the determining unit 43 stores the acquired blood sugar equivalent value of the user in the storage 13 in association with the date and time of acquisition and the abnormal tendency (step ST21). Furthermore, the obtained blood sugar equivalent value of the user is associated with the acquisition date and time, abnormal tendency, and selected test candidate, and processed so that the user cannot be identified, and sent to the test server 6 (step ST22), and the process ends. do. Note that when an image of the meal is acquired, the image is also transmitted to the inspection server 6. In the inspection server 6, the acquired information is accumulated.

In this way, in this embodiment, it is determined whether or not the user's blood sugar equivalent value has an abnormal tendency, and if the user's blood sugar equivalent value has an abnormal tendency, test candidates for acquiring biological information related to the blood sugar equivalent value are selected. The user is now presented with multiple action candidates, including: Thereby, the user can take actions including conducting a test according to the abnormal tendency of his/her own blood sugar level. Furthermore, the user no longer performs tests that do not match the abnormal tendency of his or her own blood sugar level. Therefore, personalized medicine tailored to the user can be promoted.

In addition, by presenting multiple action candidates including test candidates that can obtain biological information related to blood sugar equivalent values with higher accuracy than measuring devices 3 and 4, users can accurately assess their own blood sugar status. Tests that can be understood can be selected. Therefore, by taking the selected test, the user can more accurately understand his or her own blood sugar status.

In addition, by accepting the specification of at least one item that serves as an index when selecting a test candidate, and presenting the test candidates in a display format according to the specified item, the user can Test candidates can be presented in a display format that reflects the desired items. Therefore, the user can easily select test candidates.

In addition, the user is presented with a question to determine the display position of the test candidate on the scale according to the specified item, and the display position of the test candidate on the scale is determined according to the answer to the question. By presenting test candidates to the user in a display format that displays an icon representing the test candidate at the display position determined above, the test candidates are displayed in a display format that reflects the items that serve as indicators when selecting a test candidate. can be presented to the user. Therefore, the user can select test candidates by considering the items that he or she considers important.

In addition, the system accepts the specification of at least one additional item that will serve as an index when selecting a test candidate, and updates the display format of the icon representing the test candidate according to the additionally specified item, allowing the user to select the test candidate. By presenting the test candidates, it is possible to present the test candidates in a display format that takes into consideration a plurality of items that serve as indicators when selecting test candidates. Therefore, the user can easily select test candidates.

Furthermore, by presenting the user with statistical information on test candidates selected in the past, the user can more easily select a test method suitable for him/herself.

Furthermore, by accumulating blood sugar equivalent values, abnormal trends, selected test candidates, images of meals, etc. in the test server 6, it becomes possible to use the accumulated information as big data. The accumulated big data can be used for training AI that provides information related to blood sugar levels, or used as statistical information.

Note that in the first embodiment, if the user selects the testing method (3), the user has a blood glucose meter. For this reason, it is preferable that the mobile terminal 2 periodically notify the user that the blood sugar level will be measured.

In addition, in the first embodiment described above, guidance is provided and the process ends when the user selects a test from the test candidates, but action candidates that further step up the test selected by the user may be proposed. For example, as shown in FIG. 11, when five test candidates are presented when the postprandial hyperglycemia spike is large and the user selects home blood glucose level measurement, the next action candidate is the test method ( It may be possible to guide the specialized tests (GA test and 1,5AG test) at the hospital described in 11) or the specialized test (glucose tolerance test) at the hospital described in test method (12). FIG. 23 is a diagram showing a guidance screen for the next examination. As shown in FIG. 23, the guidance screen 85 displays that the user has selected home blood glucose level measurement, and the next step is a specialized test (for postprandial hyperglycemia) at the hospital. The display recommends two test methods: (GA test and 1,5AG test) and a specialized test at the hospital (glucose tolerance test). Referring to the guidance screen 85, the user can perform a specialized test at the hospital (GA test and 1,5AG test) or a specialized test at the hospital (glucose tolerance test) after self-collected blood glucose level measurement at home. ) can be recognized as preferable.

Note that in the first embodiment, the test method (2) when careful attention is required to the blood sugar level is a urine sugar test. Urine sugar tests are not as accurate as blood sugar levels measured by blood sampling. For this reason, if the user selects the urine sugar test and the blood sugar level is determined to be abnormal as a result of the urine sugar test, it is preferable to prompt the user to have the user measure the blood sugar level by drawing blood. . In this case, by displaying an inquiry screen 86 shown in FIG. 24 that inquires of the user about the results of the urine sugar test, the user is asked about the results of the urine sugar test, and if "No abnormality" is selected, action candidates are presented. If ``abnormality'' is selected after ``abnormality'' is completed, action candidates for a case where the postprandial hyperglycemia spike is large as shown in FIG. 11 may be presented to the user.

Furthermore, in the first embodiment, it may not be possible to determine whether or not the blood sugar level tends to be abnormal, for example, due to a lack of measured values of blood sugar equivalent values. For example, the user may not be able to monitor the blood glucose equivalent value enough to determine a postprandial hyperglycemic spike because the user wears the measuring device 3 for a short time, or the fasting blood glucose equivalent value may not be monitored. In such a case, the determination unit 42 cannot determine whether there is an abnormal tendency. For this reason, if the determining unit 42 cannot determine whether there is an abnormal tendency, it is preferable to issue a notification urging the user to increase the wearing time of the measuring device 3. FIG. 25 is a diagram showing a notification screen. As shown in FIG. 25, the notification screen 87 displays a notification 88 that says "Please increase the time you wear the measuring device." The user can take action to increase the wearing time of the measuring device 3 using the notification screen 87, thereby making it possible to determine whether or not the subsequent blood sugar equivalent value tends to be abnormal. .

In addition, in the first embodiment, each time an item is selected as an index for selecting a test candidate on the item list screen 60, test candidates are presented to the user in a display format using a scale. However, it is not limited to this. In the item list screen 60, a plurality of items may be selected at once. In this case, the display position of the test candidate on the scale of each of the selected items is determined, and the test candidate is presented to the user in a display format that displays the test candidate icon at the determined display position. Become.

In addition, in the first embodiment, when the item selection button 55 is selected, the item list screen 60 is displayed to prompt the user to select an item that will serve as an index when selecting a test candidate. It is not limited to. Before the blood sugar equivalent value is monitored by the test support device according to the present embodiment, the user may be made to select in advance an item that will serve as an index when selecting a test candidate. In this case, a button replacing the item selection button 55 is displayed on the action candidate presentation screen 52, and by selecting that button, test candidates are presented to the user in the display format shown in FIG. 17 or 20. becomes.

Note that when the user is asked to select in advance items that serve as indicators for selecting test candidates, the user may select items that include risk checks for various diseases. In such a case, the determining unit 43 may include test candidates including the same multi-item test as in the case where the fasting blood sugar level is high in the action candidates.

In addition, in the first embodiment, when an item that is an index for selecting a test candidate is selected on the item list screen 60, a question is asked of the user, and according to the answer to the question, the test candidate is selected on the scale. However, the display position is not limited to this. The display position of the test candidate on the scale may be determined according to the degree of desirability of the selected item without asking any questions. For example, if the user selects a feeling of security after blood collection, the display position is determined so that the icon for a test candidate for blood collection at a hospital is displayed at a position that provides a higher sense of security on the scale representing a sense of security. be done.

Further, in the first embodiment, the item list screen 60 may display items that serve as indicators when selecting action candidates including not only test candidates but also recommended actions. In this case, the display position of the action candidate on the scale may be determined according to the selected item, and the icon of the action candidate may be displayed at the determined display position.

In addition, in the first embodiment, when the blood sugar equivalent value does not have an abnormal trend, a notification saying "The blood sugar level does not have an abnormal trend. Please continue with your current lifestyle" is sent as shown in FIG. However, the content of the notification is not limited to this. If the blood sugar equivalent value does not have an abnormal tendency, but there is a tendency for the blood sugar equivalent value to increase, it is preferable to provide a notification that includes advice to be careful about lifestyle habits.

Further, in the first embodiment, the blood sugar equivalent value is measured using the measuring devices 3 and 4, but the present invention is not limited to this. Instead of measuring the blood sugar equivalent value using the measuring devices 3 and 4, a urine sugar test may be performed to measure the urine sugar. In this case, the measured urine sugar value is an example of the first biological information. In the case of a urine sugar test, if a urine sugar test device is used, a urine sugar value can be obtained, and this can be used as a blood sugar equivalent value. A urine sugar test device is an example of a measuring device. In this case, the urine sugar test device is provided with a communication function with the mobile terminal 2, and the measured urine sugar value is sent to the mobile terminal 2, and the blood sugar equivalent value is monitored by the urine sugar value on the mobile terminal 2. do it.

On the other hand, when performing a urine sugar test using a test strip, the color of the test strip changes depending on the amount of sugar in the urine. In this case, an image of the test paper is acquired by photographing the test paper with the camera 18 of the mobile terminal 2, and the determination unit 42 determines the abnormal tendency by recognizing the color of the test paper from the image of the test paper. Just do it. In this case, since a measuring device is not required, inspection support can be provided only by the mobile terminal 2. Therefore, the user does not need to prepare measuring devices 3, 4 or a urine sugar testing device.

Further, instead of the blood sugar equivalent value measured by the measuring devices 3 and 4, the blood sugar equivalent value may be monitored by using an AGP (Ambulatory glucose profile). AGP is a useful analysis method for reading blood sugar fluctuation trends, that is, blood sugar trends, from blood sugar levels or glucose levels in interstitial fluid obtained through continuous measurement over several days (https://dm -net.co.jp/trend/agp/001.php). AGP makes it easy to understand times of the day when hypoglycemia and hyperglycemia are likely to occur, as well as times when blood sugar levels fluctuate greatly. Therefore, by monitoring the blood sugar equivalent value using AGP, it is possible to easily determine an abnormal tendency in the blood sugar equivalent value.

Further, in the first embodiment, the blood sugar equivalent value measured by the measuring devices 3 and 4 is monitored, and the user is presented with a comparison result between the monitoring result of the blood sugar equivalent value and the test result conducted by the user by blood sampling. You can also do this. FIG. 26 is a diagram showing a comparison result between the monitoring result of blood sugar equivalent value and the test result conducted by the user by blood sampling. In FIG. 26, the solid line indicates the monitoring results corresponding to the blood sugar level, and the broken line indicates the test results performed by blood sampling. As shown in FIG. 26, the blood sugar equivalent values measured by the measuring devices 3 and 4 tend to be higher than the actual blood sugar. As shown in FIG. 26, by presenting the user with the results of comparison between the blood sugar equivalent value monitoring results and the test results performed by the user through blood sampling, the user can compare the current blood sugar equivalent value with the actual blood sugar level. It is possible to judge the discrepancy between the two.

Further, in the first embodiment, a postprandial hyperglycemia spike is determined as an abnormal tendency of the blood sugar equivalent value, but the present invention is not limited to this. As the abnormal tendency determined by monitoring the blood sugar equivalent value, fasting hyperglycemia, hypoglycemia, nocturnal hyperglycemia, etc. may be determined. For example, in the case of hypoglycemia, suggested test candidates include a 5-hour stress test, salivary cortisol test, salivary cortisol + DHEA test, delayed food allergy test, and organic aciduria measurement. The 5-hour stress test is almost an essential test for hypoglycemia. A salivary cortisol test is a test that determines whether a person is in a state of fatigue due to stress. The DHEA test is a test for dehydroepiandrosterone sulfate. Dehydroepiandrosterone sulfate is a type of male hormone. Delayed food allergy testing is a test to determine the severity of intestinal disorders. Organic aciduria measurement is a test to determine whether fungi are multiplying in the intestinal tract and producing toxins.

[Second embodiment]
In the first embodiment, a mode has been described in which action candidates including test candidates for acquiring biological information related to blood sugar equivalent values are presented to the user according to an abnormal tendency of blood sugar equivalent values. It is not limited to this. For example, the technology of the present disclosure may be applied to a form in which action candidates including test candidates for acquiring biological information required for diagnosing various diseases such as infectious diseases and cancer are presented to the user. Good too. It is known that among various diseases, when contracted, certain physiological information such as heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial blood oxygen saturation, and body temperature tend to be abnormal. In particular, if the technology of this embodiment can determine abnormal trends in various physiological information before the user becomes aware of the symptoms of the disease, and if there is an abnormal trend, the user can be recommended to undergo various tests, this will contribute to early detection of the disease. can.

Hereinafter, an example in which the new coronavirus infection (COVID-19) is applied will be explained as a specific example of such a disease. In this embodiment, heartbeat is used as the first biological information instead of the blood sugar equivalent value in the first embodiment. It is assumed that the heartbeat is acquired by a sensor included in the measuring device 3. Furthermore, instead of glucose, urine sugar, blood sugar level, HbA1c, glycoalbumin, and 1,5AG in the first embodiment, test results regarding the presence or absence of infection with the new coronavirus are applied as second biological information. In this embodiment, some redundant explanations of the same configurations and operations as in the first embodiment will be omitted.

FIG. 27 is a schematic diagram illustrating an example of changes in heart rate variability (HRV), internal virus amount, internal antibody amount, and virus excretion amount of a person suffering from the new coronavirus infection. In FIG. 27, the heart rate fluctuation is shown as a thick solid line, the amount of virus in the body is shown as a thin solid line, the amount of antibodies in the body is shown as a dashed line, and the amount of virus excreted is shown as a broken line. On the horizontal axis of FIG. 27, the day of onset of symptoms such as fever and cough is set as day 0, and days after the onset of symptoms are expressed as positive and days before onset are expressed as negative. Heart rate variability is a value representing the variation in the time interval (RRI: R-R Interval) of each heartbeat. Specifically, heart rate variability is determined by the standard deviation of the R-R interval (SDNN) over a predetermined period and/or the root mean square of the difference between two consecutive RRIs (rMSSD). Mean Square of Successive R-R interval Differences), etc.

As shown in FIG. 27, in the case of a new coronavirus infection, the amount of virus in the body begins to rapidly increase about five days before the onset of the disease, and as a result, heart rate variability shows an abnormal tendency to decrease. This is because non-infected people experience fluctuations in heart rate, such as increased heart rate during exercise and stress, and decreased heart rate when relaxed, but infected people have poor heart rate tracking and their heart rate decreases. This is because the degree of increase and decrease becomes smaller. After that, around the day of onset, the amount of virus in the body reaches its maximum value, and heart rate variability reaches its minimum value. Approximately 10 days after the day of onset, the amount of antibodies in the body increases, the amount of virus in the body begins to decrease, and heart rate variability gradually decreases. return to normal.

The information acquisition unit 41 acquires the heartbeat transmitted from the communication I/F 25 of the measuring device 3 by receiving it through the communication I/F 15 . Note that since the measuring device 3 basically transmits the heartbeat at all times, that is, at predetermined time intervals, the information acquisition unit 41 always acquires the heartbeat. The heartbeat acquired by the information acquisition unit 41 is stored in the storage 13 in association with the date and time of acquisition.

The determination unit 42 determines whether or not the heartbeat tends to be abnormal by monitoring the heartbeat acquired by the information acquisition unit 41. Specifically, the determination unit 42 monitors the heartbeat transmitted from the measuring device 3, calculates heart rate variability from the monitored heartbeat, and when the heart rate variability becomes equal to or less than a predetermined threshold Th11, It is determined that the heartbeat tends to be abnormal. Further, the determining unit 42 determines that the degree of abnormal heart rate tendency is large when the heart rate variation is below the threshold Th12 (Th12<Th11), and when the heart rate variation is below the threshold Th11 and exceeds Th12. It is determined that the degree of abnormal heart rate tendency is small.

Further, the determination unit 42 may determine the abnormality tendency of the heartbeat using representative values such as the average value and the median value of the heartbeat fluctuation for each predetermined period (for example, 6 hours). This is because it is preferable not to regard a temporary increase in heart rate variability during exercise or under stress as an abnormal tendency.

In addition, when there is a situation where the heart rate variability is increasing (becoming equal to or higher than the threshold value Th11), the determining unit 42 determines whether the increase is temporary due to exercise, tension, etc. If it is determined that the increase is temporary, the period of increase may be excluded and it may be determined whether or not the heartbeat tends to be abnormal. Determination as to whether heart rate variability is a temporary increase may be made by comparing with a previous tendency for a temporary increase in heart rate variability in a similar situation. Specifically, for example, a temporary increase pattern of heart rate variability is stored in the storage 13 in advance, and the determination unit 42 compares the stored increase pattern with the heart rate variability during monitoring to determine whether the heart rate variability is It may also be determined whether the increase is temporary.

The determining unit 43 determines a plurality of action candidates to be recommended to the user when the determining unit 42 determines that the heartbeat tends to be abnormal. The action candidates include at least one test candidate for obtaining test results regarding the presence or absence of infection with the new coronavirus.

A specific example of a method for determining test candidates by the determination unit 43 will be described with reference to FIG. 28. FIG. 28 is a table showing testing methods related to the new coronavirus infection. In FIG. 28, the specimen type, testing location, availability of self-collection, cost, required time, and acquired biological information are shown as testing information for nine testing methods (C1) to (C9). The table shown in FIG. 28 is stored in the storage 13 as a table, for example. Note that the content in Figure 28 is an example, and the test information, evaluation of each item, and conditions may be updated as appropriate depending on the epidemic status of the new coronavirus infection, treatment status, progress status of testing methods, etc. .

Test methods (C1) to (C3) are PCR (Polymerase Chain Reaction) tests using a nasopharyngeal swab, a nasal cavity swab, and saliva as subjects, respectively. Test methods (C4) to (C6) are quantitative antigen tests using nasopharyngeal swab, nasal cavity swab, and saliva as subjects, respectively. Test methods (C7) to (C8) are antigen qualitative tests using nasopharyngeal swabs and nasal cavity swabs as subjects, respectively. Test methods (C1) to (C8) can obtain test results as second biological information to determine whether a person is currently infected with the new coronavirus infection. The test method (C9) is an antibody test using blood as a specimen, and the test result as to whether the person has been infected with the new coronavirus infection in the past can be obtained as second biological information. The determining unit 43 selects a test candidate from a plurality of test methods (C1) to (C9) that include such specification of the type of test subject and for acquiring second biological information from the test subject. Determine exactly.

Further, FIG. 28 shows various items that serve as indicators when the user selects the presented test candidates. Definitions of various items and evaluation methods are the same as in the first embodiment, so descriptions thereof will be omitted. However, regarding accuracy, the higher the degree to which a positive person can be detected as positive (so-called sensitivity), the higher the degree of desirability.

Further, FIG. 28 shows various conditions when the determining unit 43 determines test candidates. Specifically, conditions regarding the testable period and suitability of testing for those with a small tendency toward abnormalities, asymptomatic individuals, and high-risk individuals are indicated. The "testable period" indicates the period during which the degree of detection (so-called sensitivity) is relatively high and the test results can be trusted when testing a positive person. “A person with a small abnormal tendency” is a person who has been determined by the determining unit 42 to have a small abnormal tendency. "Asymptomatic person" means a person who has not developed symptoms such as fever and cough. For people with small abnormalities and asymptomatic people, testing methods with relatively low sensitivity should be used to prevent oversight due to false negatives, so testing methods with relatively low sensitivity are not allowed. "High-risk individuals" are those who have risk factors such as aggravation of the disease and difficulty in treating the disease, and include, for example, the elderly, those with underlying diseases, and pregnant women. For high-risk individuals, testing should be more accurate in order to provide appropriate treatment quickly, so testing methods with relatively low sensitivity are no longer acceptable.

The determining unit 43 refers to the table in FIG. 28 and determines, as an inspection candidate, an inspection method suitable for various conditions among inspection methods (C1) to (C9). As shown in FIG. 28, in the case of the new coronavirus infection, the testable period is determined based on the date of onset of the disease. Therefore, first, the determining unit 43 estimates the date of onset based on heart rate variability, and determines test candidates depending on whether the current time is included in the testable period based on the estimated date of onset. For example, if it is estimated that the current time is two days before the onset date, the determining unit 43 determines test methods (C1) to (C5) as test candidates. Further, for example, if it is estimated that the current time is four days after the onset of symptoms, the determining unit 43 determines the test methods (C1) to (C8) as test candidates. For example, if it is estimated that the current time is 15 days or more after the onset date, the determining unit 43 determines the test method (C9) as a test candidate.

As a method for estimating the date of onset, for example, based on the fact that there is a time lag of about 5 days from when heart rate variability begins to show an abnormal tendency until the onset of the disease (see FIG. 27), the determination unit 42 determines that the heart rate is in an abnormal tendency. The onset date may be estimated to be approximately 5 days after the onset of symptoms. For example, a learning model is trained using a pair of the heart rate variability transition data of a person infected with the new coronavirus infection and the actual onset date as learning data, and the heart rate variability transition data is input. A learning model that outputs the estimated date of onset may be used.

Second, the determining unit 43 determines test candidates according to the degree of abnormal heartbeat tendency determined by the determining unit 42. For example, when the determination unit 42 determines that the abnormality tendency is small, the determination unit 43 determines inspection methods (C1), (C3), (C4), (C6), and (C9) as inspection candidates. Further, the determining unit 43 determines test candidates in the same manner even when the user is asymptomatic. On the other hand, if the determination unit 42 determines that the abnormality tendency is large, the determination unit 43 determines the inspection methods (C1) to (C9) as inspection candidates.

Thirdly, the determining unit 43 determines test candidates according to risk factors possessed by the user. For example, if the user is a high-risk person, the determining unit 43 determines test methods (C1) to (C6) and (C9) as test candidates. On the other hand, if the user is not a high-risk person, the determining unit 43 determines testing methods (C1) to (C9) as testing candidates.

According to the first to third decisions above, the determining unit 43 determines the final test candidates. For example, if the current time is 4 days after the onset date, and the determining unit 42 determines that the abnormality tendency is large, and the user is symptomatic and not a high-risk person, the determining unit 43 selects the testing methods (C1 to 1). C8) is determined as a test candidate. For example, if the current time is four days after the onset date, the determination unit 42 determines that the abnormality tendency is large, and the user is asymptomatic and a high-risk person, the determination unit 43 selects the test method (C1), (C3), (C4), and (C6) are determined as test candidates.

The presentation unit 44 presents a plurality of action candidates including the test candidates determined by the determination unit 43 to the user. Figures 29 and 30 show a presentation screen that presents test candidates to the user in a display format that displays test candidate icons on a scale when the user selects two items, "Cost" and "Accuracy." It is a figure showing an example. On the presentation screen 76X of FIGS. 29 and 30, a scale 69X representing accuracy is displayed orthogonal to a scale 77 representing cost, and icons 701 to 708 of test candidates are arranged in a two-dimensional manner according to cost and accuracy. Is displayed. Icons 701 to 708 correspond to inspection methods (C1) to (C8), respectively.

FIG. 29 is a presentation screen when the current time is four days after the onset date, the determination unit 42 determines that the abnormality tendency is large, and the user is a symptomatic person and not a high-risk person. FIG. 30 is a presentation screen when the current time is four days after the onset date, the determination unit 42 determines that the abnormal tendency is large, and the user is asymptomatic and at high risk. The presentation screen 76X allows the user to recognize the cost and accuracy of the presented test candidates at a glance. Thereby, test candidates can be easily compared in consideration of both cost and accuracy.

In addition, if the determining unit 43 determines that none of the test methods are suitable, such as when the current time is three days or less before the onset date, the presenting unit 44 may present a notification to that effect as an action candidate. good. For example, the notification may read, ``There is an abnormal tendency in the heart rate, but at this time, accurate results cannot be obtained even if the test is performed.Let's continue monitoring the heart rate.'' Furthermore, when the determining unit 42 determines that the heartbeat does not tend to be abnormal, the presenting unit 44 may present a notification to that effect as an action candidate. For example, the notification may read, "Currently, there is no abnormality in the heart rate. Please continue to take precautions against infection."

In this way, in this embodiment, it is determined whether or not the user's heartbeat tends to be abnormal, and if the heartbeat of the user is abnormal, test results regarding the presence or absence of infection with the new coronavirus infection related to the heartbeat are obtained. multiple action candidates, including test candidates, are presented to the user. Thereby, the user can take actions including conducting a test according to the abnormality tendency of the user's own heartbeat. In particular, in the case of a new coronavirus infection, the amount of virus excreted by an infected person, that is, the infectivity to others, peaks around the date of onset (see Figure 27), so abnormal trends in heartbeat are determined before the date of onset. , by suggesting users to undergo testing, it can contribute to preventing the spread of infection.

Note that in the second embodiment, the determination unit 42 determines the abnormal tendency of heartbeat based on heart rate variability, but the present invention is not limited to this. The determining unit 42 determines that the heart rate tends to be abnormal when the value of the heart rate is equal to or higher than a predetermined threshold for a predetermined period (for example, 3 days) instead of the heart rate variability. Good too. This configuration can contribute to early detection of diseases in which the heart rate remains high during the onset of the disease. In addition, instead of the heart rate fluctuation, the determination unit 42 determines that the time fluctuation of the heart rate (the difference between the maximum value and the minimum value of the heart rate in a predetermined period (for example, 3 days)) is greater than or equal to a predetermined threshold value. In this case, it may be determined that the heartbeat tends to be abnormal. This type of configuration can contribute to early detection of diseases in which the heart rate increases rapidly during the onset of the disease.

Further, in the second embodiment, a case has been described in which heartbeat is applied as the first biological information, but the present invention is not limited to this. In the second embodiment, at least one of physiological information such as heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial oxygen saturation, and body temperature may be applied as the first biological information. This physiological information is acquired, for example, by a sensor included in a wearable terminal such as a smart watch.

Further, in the second embodiment, a case has been described in which test results regarding the presence or absence of infection with the new coronavirus are applied as the second biological information, but the present invention is not limited to this. In the second embodiment, the user's disease diagnosis result may be applied as the second biological information related to physiological information. "Disease diagnosis results" include, for example, component analysis results of the user's body fluids such as blood, urine, stool, nasopharyngeal swabs, nasal cavity swabs, and saliva, as well as pathogens such as viruses and bacteria. detection results can be applied. For example, methods such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound can be used to examine organs such as the user's stomach, large intestine, lungs, uterus, and breasts. It is possible to apply the interpretation results of images taken by .

Furthermore, in the second embodiment described above, diagnosis results of a plurality of different types of diseases may be applied as the second biological information related to physiological information. For example, both a test related to a new coronavirus infection and a test related to an influenza virus infection may be presented as test candidates. Further, an action candidate for simultaneously undergoing tests related to a plurality of different types of diseases may be presented. In these cases, diagnosis of various diseases can be recommended, which can contribute to early detection of diseases.

Further, in the second embodiment, the date of onset and information as to whether the user is an asymptomatic person or a high-risk person may be inputted by the user via the touch panel 14, for example. FIG. 31 is a diagram showing a question presentation screen for inputting these. As shown in FIG. 31, four questions Q1 to Q4 are displayed on the question presentation screen 65X. The user answers YES or NO to questions Q1 to Q4. When question Q1 is YES, the determining unit 43 specifies the onset date by inputting the onset date into the input box 67X. If the question Q1 is NO, the determining unit 43 specifies that the user is asymptomatic. If at least one of the questions Q2 to Q4 is YES, the determining unit 43 identifies the user as a high-risk person. When the user selects the end answer button 66 after answering, the determining unit 43 determines test candidates according to the answer results of the four questions Q1 to Q4.

In addition, in the second embodiment, whether the user is asymptomatic or not is determined based on the fact that there is a time lag of about 5 days from when the heartbeat shows an abnormal tendency until the onset of symptoms (see FIG. 27). The determination unit 43 may estimate. For example, if the present moment is the second day after the heartbeat started showing an abnormal tendency, the determining unit 43 may estimate that the user is an asymptomatic person who has not yet developed symptoms. Alternatively, for example, by measuring the body temperature with the measuring device 3, the determination unit 43 may determine whether or not the person has a fever, and if the person does not have a fever, it may be assumed that the person is asymptomatic.

In addition, in the second embodiment, the determination unit 43 estimates the date of onset based on the fact that the testing period for the new coronavirus infection is determined based on the date of onset. Not limited to. For example, when testing for influenza virus infection, the period from infection to onset of symptoms is short, about 1 to 2 days, and the difference between the date when abnormal trends start to be seen in the first biological information and the date of onset is small. There is little significance in estimating the date of onset. Furthermore, for example, when various lifestyle-related diseases are to be tested, it is difficult to clearly estimate the date of onset. However, even for these diseases, the appropriate testing method may differ depending on the time that has passed since abnormal trends began to be observed. Therefore, the determining unit 43 may determine test candidates according to the elapsed time from the time when it was determined that the first biological information has an abnormal tendency to the present time.

Furthermore, in the second embodiment, whether the user is a close contact may be applied as a condition for determining test candidates. In the case of close contacts, there is a relatively high possibility that the test result will be positive, so a highly sensitive testing method should be used to prevent false negatives from being missed. Therefore, testing methods with relatively low sensitivity may be disabled. Whether the user is a close contact person may be detected by, for example, a known new coronavirus contact confirmation application.

In addition, in the second embodiment, after conducting a test to determine whether or not the person is infected with the novel coronavirus, the test results are fed back to the mobile terminal 2, so that the mobile terminal 2 determines whether or not to continue monitoring the heartbeat. You may judge. For example, if the determination unit 42 determines that the heart rate tends to be abnormal and a test for the new coronavirus infection is performed, but the test result is negative, the determination unit 42 determines that heart rate monitoring should be continued. It's okay. In particular, if the user falls under any of the following categories: those with small abnormal tendencies, asymptomatic individuals, high-risk individuals, and close contacts, there is a high risk of missed results due to false negatives and sudden changes in condition, so monitor heart rate. It is preferable to determine that it should be continued.

Specifically, the information acquisition unit 41 acquires test results regarding the presence or absence of infection with the new coronavirus infection. The test results may be transmitted to the mobile terminal 2 from the testing institution, or may be input by the user via the touch panel 14, for example. If the obtained test result is negative, the presenting unit 44 determines that heartbeat monitoring should be continued, and presents a notification to that effect to the user. When monitoring of the heartbeat continues, the determination unit 42 determines whether the abnormality of the heartbeat has become more pronounced and whether the abnormality of the heartbeat continues. The determining unit 43 determines a plurality of action candidates to be recommended to the user again when the determining unit 42 determines that the abnormality of heartbeat has become noticeable or continues.

Furthermore, in the second embodiment, the presentation unit 44 may transmit the user's heartbeat data and the test candidates determined by the determination unit 43 to the testing institution to which the user has applied for the test. According to this embodiment, it is possible to assist a medical worker at a testing institution in determining whether the testing method selected by the user is appropriate.

Further, in each of the embodiments described above, the presentation unit 44 presents the action candidates to the user by displaying them on the touch panel 14, but the present invention is not limited to this. The presentation unit 44 may present action candidates to the user by voice.

Further, in each of the embodiments described above, when a user performs a health checkup, the examination support device according to each embodiment may be used. For example, the measuring instruments 3 and 4 may be given to the user about two weeks before the medical examination to monitor the first biological information. Then, when an abnormal tendency is observed in the first biological information, action candidates may be presented to the user, the user may select a test candidate, and the selected test may be performed during a health checkup.

Further, in each of the above embodiments, the first biological information measured by the measuring devices 3 and 4 is transmitted to the mobile terminal 2, and action candidates are presented to the user on the mobile terminal 2, but the present invention is not limited to this. It's not a thing. In particular, even if the test support program according to the present embodiment is installed in the wristwatch-shaped measuring device 3, and the measuring device 3 alone determines the abnormal tendency of the first biological information, determines the action candidates, and presents the action candidates. good. In this case, the measuring instrument 3 has the functional configuration of the inspection support device according to this embodiment shown in FIG.

Furthermore, in each of the above embodiments, the first biological information measured by the measuring instruments 3 and 4 is transmitted to the mobile terminal 2, and the mobile terminal 2 determines abnormal trends, determines action candidates, and presents action candidates. However, it is not limited to this. The first biological information measured by the measuring devices 3 and 4 is sent to the testing server 6 directly from the measuring devices 3 and 4 or via the mobile terminal 2, and the testing server 6 determines abnormal trends and selects action candidates. A decision may be made and action candidates may be presented. In this case, the test server 6 transmits the determined action candidates to the mobile terminal 2 or the measuring device 3, thereby presenting the action candidates to the user on the mobile terminal 2 or the measuring device 3.

Further, in each of the above embodiments, the hardware structure of a processing unit (Processing Unit) that executes various processes such as the information acquisition unit 41, determination unit 42, determination unit 43, and presentation unit 44 is as follows. The various processors shown can be used. As mentioned above, the various processors mentioned above include the CPU, which is a general-purpose processor that executes software (programs) and functions as various processing units, as well as circuits such as FPGA (Field Programmable Gate Array) after manufacturing. A programmable logic device (PLD), which is a processor whose configuration can be changed, and a dedicated electrical device, which is a processor with a circuit configuration specifically designed to execute a specific process, such as an ASIC (Application Specific Integrated Circuit) Includes circuits, etc.

One processing unit may be composed of one of these various types of processors, or a combination of two or more processors of the same type or different types (for example, a combination of multiple FPGAs or a combination of a CPU and an FPGA). ). Further, the plurality of processing units may be configured with one processor.

As an example of configuring a plurality of processing units with one processor, firstly, as typified by computers such as a client and a server, one processor is configured with a combination of one or more CPUs and software, There is a form in which this processor functions as a plurality of processing units. Second, there are processors that use a single IC (Integrated Circuit) chip to implement the functions of an entire system including multiple processing units, as typified by System On Chip (SoC). be. In this way, various processing units are configured using one or more of the various processors described above as a hardware structure.

Furthermore, as the hardware structure of these various processors, more specifically, an electric circuit (Circuitry) that is a combination of circuit elements such as semiconductor elements can be used.

1 Inspection support system 2 Mobile terminal 3, 4 Measuring device 4A Filament 5 Network 6 Inspection server 11, 21 CPU
12 Inspection support program 13 Storage 14 Touch panel 15 Communication I/F
16 Memory 17 Network I/F
18 Camera 19 Bus 22 Measurement program 23 Storage 24 Touch panel 25 Communication I/F
26 Memory 27 Network I/F
28 Sensor 29 Bus 31 Processor 32 Memory 34 Sensor 41 Information acquisition section 42 Judgment section 43 Determination section 44 Presentation section 50 Notification screen 51 Notification 52 Presentation screen 53 Action candidates 54 Statistical information reference button 55 Item selection button 56 Determination button 57 Explanation 58 Statistics Information 59 Recommended actions 60 List screen 61 Check box 62 Item specification button 65, 65 70E, 701-708 Test candidate icon 71 Confirm button 72 Item selection button 80, 81, 85 Guide screen 82 List 83 Reservation button 86 Inquiry screen 87 Notification screen 88 Notification

Claims (26)

comprising at least one processor;
The processor includes:
By monitoring the first biological information of the user, determining whether the first biological information has an abnormal tendency,
When the first biometric information has the abnormality tendency, at least one action candidate for acquiring second biometric information related to the first biometric information is a plurality of action candidates to be recommended to the user. Determine multiple action candidates including inspection candidates,
presenting the plurality of action candidates to the user ;
accepting the specification of at least one item that will serve as an index when the user selects the presented action candidate;
Present the action candidates in a display format according to the specified item.
Inspection support equipment. The test support device according to claim 1, wherein the test candidates include test candidates that can acquire the second biological information with higher accuracy than the first biological information. The item serves as an index when the user selects the test candidate included in the presented action candidates,
The test support device according to claim 1 , wherein the processor presents the test candidates in a display format according to the designated item. The processor includes:
presenting the user with a question for determining the display position of the test candidate on at least one scale according to the specified at least one item;
determining a display position of the test candidate on the scale according to the answer to the question;
The test support device according to claim 3 , wherein the test candidate is presented to the user in a display format that displays an icon representing the test candidate at the determined display position on the scale. The processor includes:
After displaying the icon representing the test candidate, it is possible to accept additional designation of the item by the user,
The test support device according to claim 4 , wherein when the item designation is added, a display form of an icon representing the test candidate is updated. 5. The processor repeats accepting a designation for adding the item, presenting a question according to the added item, and updating the display mode of the test candidate until the test candidate is selected by the user. The inspection support device described in . The above items include the cost required for the test, the sense of security when collecting the specimen, the degree of restraint during the test, whether it is invasive or non-invasive, the time required to obtain test results, and risk checks for various diseases. The inspection support device according to any one of claims 3 to 6 , including at least one of whether or not the test is accurate or not and the accuracy of the test. From claim 1, wherein the processor selectively determines the test candidate from among a plurality of test methods for acquiring the second biological information from the subject, including designation of the type of the subject. 7. The inspection support device according to any one of 7 . The test support device according to any one of claims 1 to 8 , wherein the processor determines the test candidates according to the degree of the abnormality tendency. The test according to any one of claims 1 to 9 , wherein the processor determines the test candidate according to the elapsed time from the time when it is determined that the first biological information has the abnormal tendency to the current time. Support equipment. The test support device according to any one of claims 1 to 10 , wherein the processor determines the test candidates according to risk factors possessed by the user. The test support device according to any one of claims 1 to 11 , wherein the processor presents statistical information of test candidates selected in the past to the user. The first biological information is a blood sugar equivalent value that has a correlation with a blood sugar level,
The test support device according to any one of claims 1 to 12 , wherein the second biological information includes at least one of a blood sugar level and HbA1c. The test support device according to any one of claims 1 to 13 , wherein the abnormal tendency is a postprandial hyperglycemia spike. The test support device according to claim 14 , wherein the processor determines the test candidates based on the user's meal contents. The first biological information is at least one of heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen uptake, arterial oxygen saturation, and body temperature,
The test support device according to any one of claims 1 to 12 , wherein the second biological information is a diagnosis result of the user's disease. The processor according to any one of claims 1 to 16 , wherein when it is determined that the first biological information does not have an abnormal tendency, the processor issues a notification according to the result of monitoring the first biological information. Inspection support equipment. The test support device according to any one of claims 1 to 17 , wherein the first biological information is acquired by a measuring device attached to the user. The inspection support device according to claim 18 , wherein the measuring device is wearable. The test support device according to claim 18 or 19 , wherein the processor issues a notification to increase the wearing time of the measuring device when it cannot be determined whether the first biological information has the abnormality tendency. The test support device according to any one of claims 1 to 17 , further comprising a sensor that acquires the first biological information. The inspection support device according to claim 21 , which is wearable. The test support device according to any one of claims 1 to 22 , wherein the action candidate further includes a recommended action for the user. The processor includes:
acquiring the second biological information;
The test support device according to any one of claims 1 to 23 , wherein it is determined whether monitoring of the first biological information should be continued depending on the acquired second biological information. By monitoring the first biological information of the user, determining whether the first biological information has an abnormal tendency,
When the first biometric information has the abnormality tendency, at least one action candidate for acquiring second biometric information related to the first biometric information is a plurality of action candidates to be recommended to the user. Determine multiple action candidates including inspection candidates,
presenting the plurality of action candidates to the user ;
accepting the specification of at least one item that will serve as an index when the user selects the presented action candidate;
Present the action candidates in a display format according to the specified item.
Inspection support method. a step of determining whether or not the first biological information tends to be abnormal by monitoring the first biological information of the user;
When the first biometric information has the abnormality tendency, at least one action candidate for acquiring second biometric information related to the first biometric information is a plurality of action candidates to be recommended to the user. a procedure for determining a plurality of action candidates including inspection candidates;
a step of presenting the plurality of action candidates to the user;
a step of accepting the specification of at least one item that serves as an index when the user selects the presented action candidate;
a step of presenting the action candidates in a display format according to a specified item;
An inspection support program that causes a computer to execute

Images